Repligen Corporation (RGEN) は上場企業です ヘルスケア セクターの Medical - Instruments & Supplies 業界で事業展開. 本社所在地は Waltham, MA, アメリカ. 現CEOは Olivier Loeillot.
RGEN を有する IPO日 1986-04-29, 1,778 名の正社員, に上場 NASDAQ Global Select, 時価総額 $7.38B.
Repligen Corporation is a global bioprocessing technology company that develops and commercializes systems and products for biological drug manufacturing. The company serves biopharmaceutical, life sciences, and diagnostics customers across North America, Europe, and Asia Pacific with a comprehensive portfolio including Protein A affinity chromatography resins, pre-packed chromatography columns, cell culture growth factors, filtration systems, and process analytics solutions. Its product lines—such as OPUS chromatography columns, XCell filtration systems, and SoloVPE spectroscopy platforms—support critical stages of biologic drug purification, concentration, and quality control. Repligen was founded in 1981 and is headquartered in Waltham, Massachusetts.
